Literature DB >> 28941747

Stepping out of the shadows: Oncogenic and tumor-promoting protein tyrosine phosphatases.

Ari Elson1.   

Abstract

Protein tyrosine phosphorylation is critical for proper function of cells and organisms. Phosphorylation is regulated by the concerted but generically opposing activities of tyrosine kinases (PTKs) and tyrosine phosphatases (PTPs), which ensure its proper regulation, reversibility, and ability to respond to changing physiological situations. Historically, PTKs have been associated mainly with oncogenic and pro-tumorigenic activities, leading to the generalization that protein dephosphorylation is anti-oncogenic and hence that PTPs are tumor-suppressors. In many cases PTPs do suppress tumorigenesis. However, a growing body of evidence indicates that PTPs act as dominant oncogenes and drive cell transformation in a number of contexts, while in others PTPs support transformation that is driven by other oncogenes. This review summarizes the known transforming and tumor-promoting activities of the classical, tyrosine specific PTPs and highlights their potential as drug targets for cancer therapy.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Breast cancer; Lymphoma; Oncogene; Tumor promoter; Tyrosine phosphatase

Mesh:

Substances:

Year:  2017        PMID: 28941747     DOI: 10.1016/j.biocel.2017.09.013

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  10 in total

1.  Comparative Genomics Reveals Shared Mutational Landscape in Canine Hemangiosarcoma and Human Angiosarcoma.

Authors:  Matthew Breen; Jaime F Modiano; Ingegerd Elvers; Kerstin Lindblad-Toh; Kate Megquier; Jason Turner-Maier; Ross Swofford; Jong-Hyuk Kim; Aaron L Sarver; Chao Wang; Sharadha Sakthikumar; Jeremy Johnson; Michele Koltookian; Mitzi Lewellen; Milcah C Scott; Ashley J Schulte; Luke Borst; Noriko Tonomura; Jessica Alfoldi; Corrie Painter; Rachael Thomas; Elinor K Karlsson
Journal:  Mol Cancer Res       Date:  2019-09-30       Impact factor: 5.852

Review 2.  The impact of phosphatases on proliferative and survival signaling in cancer.

Authors:  Goutham Narla; Jaya Sangodkar; Christopher B Ryder
Journal:  Cell Mol Life Sci       Date:  2018-05-03       Impact factor: 9.261

3.  High-resolution crystal structures of the D1 and D2 domains of protein tyrosine phosphatase epsilon for structure-based drug design.

Authors:  George T Lountos; Sreejith Raran-Kurussi; Bryan M Zhao; Beverly K Dyas; Terrence R Burke; Robert G Ulrich; David S Waugh
Journal:  Acta Crystallogr D Struct Biol       Date:  2018-10-02       Impact factor: 7.652

4.  A cellular target engagement assay for the characterization of SHP2 (PTPN11) phosphatase inhibitors.

Authors:  Celeste Romero; Lester J Lambert; Douglas J Sheffler; Laurent J S De Backer; Dhanya Raveendra-Panickar; Maria Celeridad; Stefan Grotegut; Socorro Rodiles; John Holleran; Eduard Sergienko; Elena B Pasquale; Nicholas D P Cosford; Lutz Tautz
Journal:  J Biol Chem       Date:  2020-01-17       Impact factor: 5.157

Review 5.  Protein tyrosine phosphatases: promising targets in pancreatic ductal adenocarcinoma.

Authors:  Mariana Tannús Ruckert; Pamela Viani de Andrade; Verena Silva Santos; Vanessa Silva Silveira
Journal:  Cell Mol Life Sci       Date:  2019-04-13       Impact factor: 9.207

Review 6.  Vanadium Compounds as PTP Inhibitors.

Authors:  Elsa Irving; Andrew W Stoker
Journal:  Molecules       Date:  2017-12-19       Impact factor: 4.411

7.  To reveal pharmacological targets and molecular mechanisms of curcumol against interstitial cystitis.

Authors:  Ka Wu; Pingyuan Wei; Meizhen Liu; Xiaoliu Liang; Min Su
Journal:  J Adv Res       Date:  2019-05-15       Impact factor: 10.479

8.  PTPRO is a therapeutic target and correlated with immune infiltrates in pancreatic cancer.

Authors:  Xuben Hou; Jintong Du; Hao Fang
Journal:  J Cancer       Date:  2021-10-30       Impact factor: 4.207

9.  SCP4-STK35/PDIK1L complex is a dual phospho-catalytic signaling dependency in acute myeloid leukemia.

Authors:  Sofya A Polyanskaya; Rosamaria Y Moreno; Bin Lu; Ruopeng Feng; Yu Yao; Seema Irani; Olaf Klingbeil; Zhaolin Yang; Yiliang Wei; Osama E Demerdash; Lukas A Benjamin; Mitchell J Weiss; Yan Jessie Zhang; Christopher R Vakoc
Journal:  Cell Rep       Date:  2022-01-11       Impact factor: 9.423

10.  The liposomal delivery of hydrophobic oxidovanadium complexes imparts highly effective cytotoxicity and differentiating capacity in neuroblastoma tumour cells.

Authors:  Elsa Irving; Aristides D Tagalakis; Ruhina Maeshima; Stephen L Hart; Simon Eaton; Ari Lehtonen; Andrew W Stoker
Journal:  Sci Rep       Date:  2020-10-07       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.